Evidence map›Paper›PMID 38542527›Full record

ArticleInternational journal of molecular sciences2024

In Silico Description of the Direct Inhibition Mechanism of Endothelial Lipase by ANGPTL3.

Linda Montavoci, Omar Ben Mariem, Simona Saporiti, Tommaso Laurenzi, Luca Palazzolo, Alice Federica Ossoli, Uliano Guerrini, Laura Calabresi, Ivano Eberini

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Linda MontavociDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-7484-5311
Omar Ben MariemDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-5210-8089
Simona SaporitiAnalytical Excellence and Program Management, Merck Serono S.p.A., Via Luigi Einaudi 11, Guidonia Montecelio, 00012 Rome, Italy.ORCID 0000-0002-2096-1066
Tommaso LaurenziDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0002-0446-0392
Luca PalazzoloDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0002-5370-9588
Alice Federica OssoliCentro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.
Uliano GuerriniDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-7291-5160
Laura CalabresiCentro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-5042-9532
Ivano EberiniDipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via Giuseppe Balzaretti 9, 20133 Milan, Italy.ORCID 0000-0001-5521-3829
University of Milan · ITMerck Serono (Italy) · IT

Funding

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano PSR 2022 - Azione AMIUR Progetto Eccellenza 2023-2027
6 · The paper itself

Abstract

Angiopoietin-like protein 3 (ANGPTL3) is a plasmatic protein that plays a crucial role in lipoprotein metabolism by inhibiting the lipoprotein lipase (LPL) and the endothelial lipase (EL) responsible for the hydrolysis of phospholipids on high-density lipoprotein (HDL). Interest in developing new pharmacological therapies aimed at inhibiting ANGPTL3 has been growing due to the hypolipidemic and antiatherogenic profile observed in its absence. The goal of this study was the in silico characterization of the interaction between ANGPTL3 and EL. Because of the lack of any structural information on both the trimeric coiled-coil N-terminal domain of ANGPTL3 and the EL homodimer as well as data regarding their interactions, the first step was to obtain the three-dimensional model of these two proteins. The models were then refined via molecular dynamics (MD) simulations and used to investigate the interaction mechanism. The analysis of interactions in different docking poses and their refinement via MD allowed the identification of three specific glutamates of ANGPTL3 that recognize a positively charged patch on the surface of EL. These ANGPTL3 key residues, i.e., Glu154, Glu157, and Glu160, could form a putative molecular recognition site for EL. This study paves the way for future investigations aimed at confirming the recognition site and at designing novel inhibitors of ANGPTL3.

Indexed as

Angiopoietin-Like Protein 3LipaseAngiopoietin-like ProteinsAngiopoietinsLipoprotein LipaseLipoproteins, HDLPhospholipidsTriglyceridesAngiopoietin-Like Protein 3Angiopoietin-like ProteinsAngiopoietinsLipaseLipoprotein LipaseLipoproteins, HDLPhospholipidsTriglyceridesANGPTL3endothelial lipaseHDL remodelinglipid metabolismmolecular dynamicsprotein–protein docking

Identifiers

PMID38542527
PMCPMC10971391
OpenAlexW4393040053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.